Risk surveillance and mitigation: autoantibodies as triggers and inhibitors of severe reactions to SARS-CoV-2 infection

COVID-19 clinical presentation differs considerably between individuals, ranging from asymptomatic, mild/moderate and severe disease which in some cases are fatal or result in long-term effects. Identifying immune mechanisms behind severe disease development informs screening strategies to predict w...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Catherine, Amelia, Aisah, Ashdown, George W., Mueller, Ivo, Coussens, Anna K., Eriksson, Emily M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Mini-Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686808/
https://www.ncbi.nlm.nih.gov/pubmed/34930107
http://dx.doi.org/10.1186/s10020-021-00422-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686808/
https://www.ncbi.nlm.nih.gov/pubmed/34930107
http://dx.doi.org/10.1186/s10020-021-00422-z

Ejemplares similares